Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
1. A method for inhibiting the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein comprising contacting an EBNA1 protein with an effective amount of a compound of Formula III:
wherein R 7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group, so that the activity of the EBNA1 protein is inhibited.
2. A method for treating a latent Epstein-Barr virus infection comprising administering to a subject having a latent Epstein-Barr virus infection a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula III:
wherein R 7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group, so that the subject's latent Epstein-Barr virus infection is treated.
3. The method of claim 2 , wherein the latent Epstein-Barr virus infection is associated with cancer.